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ABSTRACT  
The hypoxia-sensitive endothelin (ET) system plays an important role in circulatory 
regulation through vasoconstrictor ETA and ETB2 and vasodilator ETB1 receptors. Sepsis 
progression is associated with microcirculatory and mitochondrial disturbances along with 
tissue hypoxia. Our aim was to investigate the consequences of treatments with the ETA 
receptor (ETA-R) antagonist, ETB1 receptor (ETB1-R) agonist, or their combination on oxygen 
dynamics, mesenteric microcirculation and mitochondrial respiration in a rodent model of 
sepsis. Sprague Dawley rats were subjected to fecal peritonitis (0.6 g kg-1 ip) or a sham 
operation. Septic animals were treated with saline or the ETA-R antagonist ETR-p1/fl peptide 
(100 nmol kg-1 iv), the ETB1-R agonist IRL-1620 (0.55 nmol kg-1 iv), or a combination 
therapy 22 h after induction. Invasive hemodynamic monitoring and blood gas analysis were 
performed during a 90-min observation, plasma ET-1 levels were determined, and intestinal 
capillary perfusion (CPR) was detected by intravital videomicroscopy. Mitochondrial 
Complex I (CI)- and CII-linked oxidative phosphorylation (OXPHOS) was evaluated by 
high-resolution respirometry in liver biopsies. Septic animals were hypotensive with elevated 
plasma ET-1. The ileal CPR, oxygen extraction (ExO2), and CI–CII-linked OXPHOS 
capacities decreased. ETR-p1/fl treatment increased ExO2 (by >45%), CPR, and CII-linked 
OXPHOS capacity. The administration of IRL-1620 countervailed the sepsis-induced 
hypotension (by >30%), normalized ExO2, and increased CPR. The combined ETA-R 
antagonist–ETB1-R agonist therapy reduced the plasma ET-1 level, significantly improved the 
intestinal microcirculation (by >41%), and reversed mitochondrial dysfunction. The additive 
effects of a combined ETA-R–ETB1-R-targeted therapy may offer a tool for a novel 
microcirculatory and mitochondrial resuscitation strategy in experimental sepsis. 
Keywords: fecal peritonitis, endothelin receptors, oxygen extraction, microcirculation, 
mitochondrial respiration, resuscitation, rat 
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INTRODUCTION 
Sepsis is a potentially life-threatening condition caused by a dysregulated host response to an 
infection (1). Along with its progression, the regulatory failure is frequently associated with a 
discrepancy between oxygen delivery (DO2), oxygen consumption (VO2), and a deficit in 
oxygen extraction (ExO2) at the cellular level. The basic concept of organ-protective 
therapies is therefore to increase oxygen uptake and transport, providing an adequate supply 
to meet subcellular oxygen demand (1, 2). Still, the currently-used respiratory- and 
circulatory-supportive modalities cannot always improve sepsis-induced alterations at the 
later stages, and it has been suggested that the interconnected processes lead to a combined 
microcirculatory and mitochondrial distress syndrome, which is believed to mediate end-
organ damage (3). In addition, the failing microcirculation cannot provide sufficient DO2, and 
the insufficiency of the mitochondrial electron transport system (ETS) cannot sustain the 
adequate aerobic metabolism of the organs (3). In recent years, the bi-directional interaction 
between the microcirculation and mitochondria has become a focus of investigations, and it 
has grown increasingly apparent to date that the mechanisms involved in microcirculatory 
and mitochondrial dysfunction are different from those implicated in the development of 
macrohemodynamic changes (3, 4). 
With this background, the major goal of our study was to design an adjunctive approach by 
which to influence the microcirculation-linked oxygen debt and energy deficit of the tissues 
during the late septic response. Specifically, we tested the hypothesis that the manipulation of 
potentially vasodilating local forces may play a role in the resuscitation of the 
microcirculation and the mitochondrial respiration as well. We have taken into account 
previous findings that elevated endothelin-1 (ET-1) levels correlate with the severity and 
mortality of sepsis both in animals and humans (5, 6). The members of the endothelial ET 
family are key peptide regulators of circulation, ET-1 being the major isoform among them 
Copyright © 2019 by the Shock Society. Unauthorized reproduction of this article is prohibited.
(7, 8). ET-1 effects are mediated by at least two types of G-protein-coupled receptors: the 
ETA receptor (ETA-R) mediates vasoconstriction, while the ETB receptor (ETB-R) mediates 
vasoconstriction (ETB2-R subtype) and vasodilation (ETB1-R subtype) (9). The ETs and ET 
receptors are involved in inflammatory events as well (10), and, more importantly, ETA-R 
antagonist treatments have potential therapeutic benefits in experimental sepsis (11) and 
ischemia-reperfusion (IR)-induced microcirculatory insufficiency (12). The functional role of 
ETB1-R is less clear. However, the stimulation of the ETB1-R also provides tissue protection 
in pro-inflammatory and IR conditions in the peripheral and central nervous system (CNS) 
(13), and this activity may also have relevant peripheral microcirculatory effects through an 
influence on the reuptake of ET-1 (8). 
Based on these findings, we hypothesized that a joint modulation of ETA-R- and ETB1-R 
transmitted effects may have an influence on microcirculatory recruitment and mitochondrial 
respiration as well. These reactions have not yet been studied in the setting of sepsis. We 
therefore examined the individual and combined effects of ETA-R antagonism and selective 
ETB1-R activation on oxygen dynamics, macro- and microcirculation, and mitochondrial ETS 
function in a clinically-relevant rodent model of sepsis (14). 
 
MATERIALS AND METHODS 
Animals 
Male Sprague Dawley rats (350 ± 30 g) were used. The animals were housed in plastic cages 
(21–23°C) with a 12/12h dark-light cycle and access to standard rodent food and water ad 
libitum. The experiments were performed in accordance with National Institutes of Health 
guidelines on the handling and care of experimental animals and EU Directive 2010/63 for 
the protection of animals used for scientific purposes (approval number V/175/2018). 
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Preparation of polymicrobial inoculum  
Polymicrobial sepsis was induced with an intraperitoneally (ip)-administered fecal inoculum. 
Briefly, 4 g of fresh rat feces was collected from different animals and suspended in 5 mL 
saline. The suspension was divided into 1 mL units, completed with sterile saline to 4 mL and 
incubated in water bath for 6 h at 37°C. Three mL incubated suspension (37°C) was filtered 
and mixed in 1 mL of agarose (2%). The concentration of the microorganisms in the 
suspension was determined (CFU mL-1) and 1.3 mL (~0.6 mg kg-1) of the mixture was 
injected ip for sepsis induction. There was no 48h mortality with these ip doses in pilot tests. 
Experimental protocol  
The animals were randomly assigned into sham-operated (Group 1, n=10) and septic (Groups 
2–5) experimental groups. Fecal peritonitis was induced in the septic groups, while the sham-
operated animals received an equal amount of sterile saline ip. All the animals received 1.5 
mL kg-1 crystalloid solution 6 h later subcutaneously to maintain fluid balance 
(Ringerfundin®, B. Braun, Melsungen, Germany) and an analgesic agent (Buprenorphine, 15 
µg kg-1, Richter Pharma, Hungary). A standardized scoring system was used 6 and 22 h after 
sepsis induction to assess the health status of the animals and to characterize the progression 
of sepsis (Supplementary Digital Content - Figure 1, http://links.lww.com/SHK/A918) (15, 
16). Twenty-two hours after induction, the animals were anesthetized with an ip mixture of 
ketamine (45.7 mg kg-1) and xylazine (9.12 mg kg-1) to start the invasive hemodynamic 
monitoring. After a 30-min recovery period and baseline measurements, the septic animals 
were randomly allocated into one or another of the following groups. Group 2 served as a 
vehicle-treated septic control and received 1 mL of saline (n=13). The next groups of septic 
animals received the ETA-R antagonist ETR-p1/fl peptide (100 nmol kg h-1; Kurabo Ltd., 
Osaka, Japan; Group 3; n=11) (17) or the highly selective ETB1-R agonist [N-Succinyl-
[Glu9,Ala11,15]endothelin1] (IRL-1620; 0.55 nmol kg-1 h-1; Sigma-Aldrich, St. Louis, MO, 
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USA; Group 4; n=11) (9). Group 5 received a combination of the ETA-R antagonist and 
ETB1-R agonist compounds in the same doses (n=10). The selection of doses was based on 
previously reported literature data (10, 11). All treatments were administered in a continuous 
60-min iv infusion in 1 mL volume, and this period was followed by an additional 30-min 
observation (Figure 1). Four animals were lost during surgical instrumentation due to 
respiratory/circulatory failure (n=1 in Sepsis + ETR-p1/fl peptide group, n=1 in Sepsis + IRL 
1620 group, and n=2 in Sepsis + ETR-p1/fl peptide+ IRL 1620 group). 
Surgical preparation and hemodynamic measurements 
The anesthetized rats were placed in a supine position on a heating pad (37°C). A 
tracheostomy was performed to provide spontaneous breathing, and the right jugular vein was 
cannulated for continuous anesthesia (ketamine 12 mg kg-1 h-1, xylazine 2.4 mg kg-1 h-1, and 
diazepam 0.576 mg kg-1 h-1), drug treatments, and infusion (Ringerfundin B. Braun; 10 mL 
kg h-1). The left carotid artery was cannulated to record the mean arterial pressure (MAP) and 
heart rate (HR). A thermistor-tip catheter was positioned into the contralateral carotid artery 
to measure core temperature and cardiac output (CO) using a thermodilution technique 
(SPEL Advanced Cardiosys 1.4, Experimetria Ltd., Budapest, Hungary). CO was indexed for 
bodyweight, while total peripheral resistance (TPR) and stroke volume index (SVI) were 
calculated according to standard formulas (TPR=MAP CO-1; SVI=CO HR-1). At the end of 
hemodynamic monitoring, arterial and venous blood samples were taken for blood gas 
analysis (Cobas b121, Roche Ltd., Basel, Switzerland). The DO2 (=CO x [(1.38 x Hb x SaO2) 
+ (0.003 x PaO2)]); VO2 (= CO x [(1.38 x Hb x (SaO2- SvO2)) + (0.003 x PaO2)]); and ExO2 
(=DO2 VO2-1) values were calculated from these parameters. The degree of lung injury was 
determined by using the PaO2/FiO2 ratio. 
After the 90-min hemodynamic monitoring period, a midline abdominal incision was 
performed to observe the intestinal microcirculation (see later). Thereafter, a liver tissue 
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biopsy was taken to evaluate mitochondrial respiratory functions, followed by blood 
sampling for blood gases and biochemical measurements. Finally, the animals were sacrificed 
under deep anesthesia. 
Intravital videomicroscopy 
An intravital orthogonal polarization spectral imaging technique (Cytoscan A/R, Cytometrics, 
Philadelphia, PA) was used to visualize the serosal microcirculation of the ileum. An empty 
ileum segment was placed on a specially designed stage, and microcirculatory images of the 
serosal surface were recorded with an S-VHS video recorder 1 (Panasonic AG-TL 700, 
Matsushita Electric Ind. Co. Ltd., Osaka, Japan). A quantitative assessment of the 
microcirculatory parameters was performed offline by frame-to-frame blinded analysis of the 
videotaped images. Changes in red blood cell velocity (RBCV) and capillary perfusion rate 
(CPR; perfused/non-perfused area) in the serosal capillaries were determined in 3 separate 
fields by means of a computer-assisted image analysis system (IVM Pictron, Budapest, 
Hungary). All the microcirculatory evaluations were performed by the same investigator 
(R.F). 
Assessment of mitochondrial respiratory function in liver homogenates 
Liver samples obtained from the left lateral lobe were washed in phosphate-buffered saline 
and then homogenized in a medium containing 250 mM sucrose, 0.5 mM Na2EDTA, 10 mM 
Tris, and 1 g L-1 bovine serum albumin. After homogenization, mitochondrial respiratory 
oxygen flux (JV,O2; pmol sec-1mL-1) normalized to 8 mg wet weight  was assessed using high-
resolution respirometry (O2k, Oroboros Instruments, Innsbruck, Austria). All the 
measurements were performed in an MiR05 respiration medium (pH 7.1) under continuous 
stirring at 37°C (18). After a stable basal respiration (without exogenous substrates and 
ADP), NADH- and succinate-supported LEAK respiration and complex I (CI)- and complex 
II (CII)-linked capacities of oxidative phosphorylation (OXPHOS I and OXPHOS II) were 
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determined in the presence of substrates (complex I-linked: 10 mM glutamate, 2 mM malate; 
and complex II: 10 mM succinate) and saturating concentration of ADP (2.5 mM). Rotenone 
(0.5 µM), an inhibitor of CI, was administered prior to the addition of succinate to block 
mitochondrial ROS production via reverse electron transport. Following stimulation of 
OXPHOS, the integrity of the outer mitochondrial membrane was evaluated with exogenous 
cytochrome c (Cytc; 10 µM). ATP synthase was blocked by oligomycin (2.5 µM) to assess 
LEAK respiration in a non-phoshorylating state (LEAKOmy). Respiratory control ratio (RCR), 
an index of coupling between respiration and phosphorylation, was expressed as a ratio of 
OXPHOS to LEAKOmy state. The ETS-independent respiration (or residual oxygen 
consumption; ROX) was determined following complex III inhibition with antimycin A (2.5 
µM). DatLab 5.1 software (Oroboros Instruments, Innsbruck, Austria) was used for online 
display, respirometry data acquisition, and analysis.  
Detection of inflammatory markers, metabolic and organ function injury  
After the liver biopsy sampling, blood samples were taken from the inferior caval vein into 
precooled, EDTA-containing tubes (1 mg mL–1), centrifuged (1200 g at 4°C for 10 min) and 
stored at -70°C until assay. Plasma levels of interleukin-6 (IL-6) and ET-1 were determined 
from these samples using commercial ELISA kits (Cusabio Biotechnology Ltd., Wuhan, 
China and Biomedica Ltd., Vienna, Austria, respectively) according to manufacturer 
instructions. The lactate level as an indicator of metabolic imbalance was measured from 
venous blood samples (Accutrend Plus Kit, Roche Diagnostics Ltd., Rotkreuz, Switzerland). 
Liver dysfunction was assessed by measuring plasma alanine aminotransferase (ALAT) and 
aspartate aminotransferase (ASAT) levels, whereas the extent of kidney injury was estimated 
my measuring plasma urea level using a Roche/Hitachi 917 analyzer (F. Hoffmann-La Roche 
AG, Switzerland). All analyses were performed on coded samples in a blinded fashion. 
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Statistical analysis  
The sample size estimation was based on a power analysis using the PS Power and Sample 
Size Calculation software (version 3.1.2). Data analysis was performed with a statistical 
software package (SigmaStat for Windows, Jandel Scientific, Erkrath, Germany). Normality 
of data distribution was analyzed with the Shapiro–Wilk test. The Friedman analysis of 
variance on ranks was applied within groups. Time-dependent differences from the baseline 
for each group were assessed with Dunn’s method. Differences between groups were 
analyzed with the Kruskal–Wallis one-way analysis of variance on ranks, followed by 
Dunn’s method. Median values and 75th and 25th percentiles are provided in the figures; P 
values <0.05 were considered significant. 
RESULTS 
Hemodynamic changes 
In the sham-operated group, there were no significant hemodynamic changes during the 
observation period. Sepsis, however, was accompanied by a significant hypotension (as 
evidenced by a temporary, approx. < 10% reduction in MAP at t=60 min, an approx. 10% 
increase in CO at the 60th and 90th min of the observation period (P < 0.05), and a >20% (P < 
0.05) decrease in TPR at t=60 min (Figure 2ACD). As compared to the vehicle-treated septic 
group, ETR-p1/fl treatment caused a non-significant elevation in the SVI (a heart rate-
independent increase in blood flow), while IRL-1620 significantly increased the MAP (by 
>30% at t=60 min vs t=0 min, P < 0.05) and TPR (by >50% at t=60 min vs t=0 min, P < 
0.05) and decreased CO (by approx. 10% at t=60 min vs sepsis at t=60 min, P < 0.05) during 
the 90-min observation period. The combined ETA-R antagonism and ETB1-R agonism 
caused significant increases in MAP and TPR values as compared to the baseline and to the 
respective values of the vehicle-treated sepsis group (Figure 2).  
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Changes in oxygen dynamics 
The 24-h septic period caused significant changes in oxygen dynamics, including an approx. 
30% increase in DO2 (P < 0.05; Figure 3A), deterioration in VO2 (by >25%, P < 0.05), and a 
>30% reduction in ExO2 values (P < 0.05) (Figure 3B-C) as compared to the sham-operated 
group. VO2 and ExO2 were significantly higher (by >35% and by nearly 50%, respectively, P 
< 0.05) after ETR-p1/fl treatment as compared to the non-treated sepsis group. A significant 
increase in ExO2 was also observed in response to IRL-1620 treatment (by nearly 50%) in 
comparison with that of the vehicle-treated sepsis group. When these treatments were 
combined, the oxygen dynamics parameters were not significantly different from those of the 
sham-operated group, and there was a statistically non-significant trend of improvement as 
compared to the non-treated sepsis group (Figure 3). 
Metabolic changes and organ dysfunctions  
Plasma ALAT activity and urea levels were significantly higher in the non-treated septic 
group as compared to the sham-operated animals (by nearly 70% and >30%, respectively, P 
< 0.05) (Figure 4A-B). Lung injury, characterized by the PaO2/FiO2 ratio, was significantly 
lower (by approx. 25%, P < 0.05) in the septic animals (Figure 4C). The ETR-p1/fl treatment 
or IRL-1620 treatment did not influence the sepsis-induced changes in plasma ALAT or urea 
levels and the PaO2/FiO2 ratio (Figure 4A–C). However, when the ETA-R antagonists and 
ETB1-R agonists were combined, the plasma ALAT level was significantly lower than in the 
vehicle-treated septic group (Figure 4A). Similar changes were observed in ASAT levels 
(data not shown). 
Likewise, polymicrobial sepsis was associated with significantly increased lactate levels (by 
>185%, P < 0.05) in the saline-treated sepsis group. In response to the ETR-p1/fl and the 
combined treatments, the lactate values were not different from those of the sham-operated 
group (Figure 4D).  
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Microcirculatory changes  
The 24-h septic insult caused significant microcirculatory deterioration in the intestinal 
serosa. The CPR reached 55%, while RBCV was approx. 60% lower than those in the sham-
operated animals (Figure 5A–B). When compared to the vehicle-treated sepsis group, ETR-
p1/fl therapy caused a significant improvement in CPR (the values were close to those of the 
sham-operated group), but not in RBCV. Agonism of the ETB1-R with IRL-1620 caused a 
slight, non-significant perfusion recovery without affecting changes in RBCV. A combination 
of the ETR-p1/fl and IRL-1620 treatments, however, was effective in restoring both 
parameters of the intestinal microcirculation (Figure 5A–B). 
Changes in inflammatory markers 
In the case of sepsis, plasma IL-6 and ET-1 levels reached higher values in comparison with 
those of the sham-operated group (by >340% and >135%, respectively, P < 0.05) (Figure 
5C–D). IRL-1620 did not influence the sepsis-induced elevations in IL-6 and ET-1, but ETR-
p1/fl treatment caused a significant reduction in plasma ET-1 level (by nearly 35%, P < 0.05). 
The combined therapy significantly reduced the sepsis-induced elevation in plasma ET-1 and 
reduced IL-6 values as well (P=0.051). 
Changes in mitochondrial function 
Intra-abdominal sepsis significantly decreased substrate oxidation as compared to the sham 
operation. In comparison with the vehicle-treated sepsis group, the ETA-R antagonist and 
ETB-R agonist therapies resulted in an increasing tendency in JV,O2, and this change was 
statistically significant after the combination of therapies (data not shown). As a result of 
septic insult, both Complex-I and Complex-II-linked OXPHOS capacity and RCR values 
were significantly lower (by approx. 40% and 70%, respectively, P < 0.05) than those in the 
sham-operated animals (Figure 6). In comparison with the non-treated sepsis group, ETR-
p1/fl treatment completely restored both CII-linked RCR and OXPHOS values (Figure 6B-D) 
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whereas IRL-1620 had no considerable effect on these parameters. In response to the 
combined treatment, however, all of the examined parameters were restored to the values of 
the sham-operated group (Figure 6). Sepsis resulted in significant disintegration of the outer 
membrane based on the effect of exogenous Cytc, but preserved membrane integrity was 
observed in the animals subjected to the combined treatment (Supplementary Digital Content 
Figure 2, http://links.lww.com/SHK/A919). 
DISCUSSION 
This is the first study to investigate the microcirculatory and mitochondrial consequences of a 
combined ETA-R antagonist–ETB1-R agonist treatment regimen in experimental sepsis. The 
protocol was designed in adherence with the recommendations of the Minimum Quality 
Threshold in Pre-clinical Sepsis Studies (MQTiPSS) guidelines with respects to proper 
analgesia, fluid resuscitation, temperature control, and humane endpoints (16). Systemic 
inflammatory activation, hemodynamic- and microcirculatory derangements, an imbalance 
between DO2 and VO2 and a reduced ExO2, organ dysfunctions and hepatic mitochondrial 
dysfunction was evident 24 h after sepsis induction. In this condition, the ETA-R antagonist 
treatment exerted no major influence on systemic hemodynamics, but effectively improved 
oxygen dynamics, ameliorated splanchnic microcirculatory dysfunction and restored the 
sepsis-induced CII-linked mitochondrial respiration. Supporting other findings, some of these 
effects can be linked to reduced inflammation (10, 19) and vasodilator effect of the ETA-R 
antagonism (20).  
When the modulation of the sepsis-activated ET system was tested with the ETB-R agonist 
IRL-1620, the reduction in MAP and TPR was effectively counteracted and furthermore, the 
treatment improved oxygen dynamics and the intestinal capillary perfusion as well. These 
findings may be explained by the tissue-dependent vasodilator- or vasoconstrictor property of 
this compound, which can be linked to the subtypes of ETB-Rs. Although it is known that 
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ETB2-Rs have a long-lasting vasopressor effect possibly due to dominant ETA-R activity (13, 
21–23), IRL-1620 shows higher affinity to the ETB1-Rs, which are expressed by the vascular 
endothelium and mediate nitric oxide-dependent vasodilatation (9). The beneficial effects of 
ETB-R agonism have already been demonstrated in acute and chronic CNS disorders (13, 21) 
and in the peripheral circulation as well, possibly linking these reactions to vasodilator effects 
(22, 24). 
In the next step in the research procedure, we examined the combined ETA-R antagonist and 
ETB1-R agonist therapy on the macro- and microhemodynamics and the main components of 
the cellular energy-providing mechanism. Combining the treatments resulted in an additive 
effect along the global oxygen supply–demand imbalance, and the microcirculatory 
parameters improved further. As a final result, organ dysfunction was significantly 
attenuated. We assume that reduced ET-1 levels caused by the combined treatment may play 
a significant role in these processes by two potential mechanisms: first, ETR-P1/fl is an 
intramolecular complementary peptide of the ETA-R and can specifically bind and block ET-
1 in the circulation (25). Second, activation of the ETB1-R stimulates the reuptake of 
circulating ET-1 (8, 23). 
Restoration of tissue perfusion and subcellular oxygen utilization are fundamental goals in 
sepsis therapy (3, 26). Vasodilator manipulation of the microcirculation can open the shunted 
or closed microcirculatory units and improve the imbalance between tissue oxygen supply 
and utilization (26). Indeed, there have been several trials of vasodilator therapies with 
contradictory results (27, 28). It has been suggested that these fiascos may stem from an 
indiscriminate application of vasoactive compounds without consideration for the phase of 
sepsis and the degree of microcirculatory dysfunction (29). The constantly recurring concern 
is timing and site specificity; the ideal sepsis therapy could increase the systemic driving 
pressure parallel to the opening of insufficient microcirculation through vasodilation (3, 29). 
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Our combined ETA-R antagonist and ETB1-R agonist treatment design has targeted this goal. 
The ETB-Rs are heterogeneously distributed in the lungs, brain, and kidneys, with specific 
dual vasoactive effects, which can contribute to the fine tuning of tissue perfusion through 
either local endothelial vasodilation or vasoconstriction (8, 13, 30). Our results suggest that if 
microcirculatory failure occurs, the specific inactivation of vasoconstrictor ETA-Rs can 
amplify the vasomodulator effects of circulating ET-1 through the ETB-Rs, leading to a 
potentially beneficial outcome at the subcellular level. On the other hand, direct activation of 
ETB-Rs can improve the capillary perfusion rate due to its local vasodilator effect or possibly 
through the increased microcirculatory driving pressure gradient as well. 
The decisive role of mitochondrial dysfunction leading to oxygen utilization disorders has 
been demonstrated in various models of endotoxemia (31) and sepsis (32, 33). A progressive 
decline in OXPHOS and ATP depletion is usually present (32, 33), and we have also detected 
a decrease in ADP-stimulated respiration 24h after sepsis induction. The over 10% increase 
in oxygen flux after exogenous Cytc administration demonstrated that the outer 
mitochondrial membrane was injured in the septic animals (34). This change in membrane 
integrity may contribute to reduced ADP-ATP conversion coupled to the ETS resulting 
decreased RCR values. Due to the fact that a marked elevation in lactate was present, it may 
well be that a metabolic switch from oxidative phosphorylation to glycolysis (the Warburg 
effect) was present (35). In this scenario, the sepsis-associated decrease in substrate oxidation 
and OXPHOS was ameliorated by ETA-R antagonist treatment. Moreover, the coupling 
between respiration and phosphorylation was improved, and the functional damage to the 
outer membrane was also mitigated. 
The precise molecular mechanism by which ETR-P1/fl exerted its mitochondrial effects is 
not known, but the regulation of Ca2+ homeostasis is a plausible mechanism. The ET 
receptors were thought to be typical G-protein-coupled plasma membrane receptors with an 
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intracellular signaling cascade, but Bkaily et al. recently demonstrated ETB-Rs in the nuclear 
membrane, suggesting more complicated intracellular mechanisms than was presumed 
previously (36). The activation of intracellular ETB-Rs can lead to an opening of R-type 
calcium channels and Na+/Ca2+ exchangers (NCX), which can separately raise the 
intranuclear and cytoplasmatic Ca2+ levels and establish a complex intracellular Ca2+ 
homeostasis. If ET-1 has such extensive intracellular effects on ion fluxes, mitochondria 
might be part of this mechanism. Accumulation of Ca2+ exceeding a critical threshold (~50 
µM) may lead to OXPHOS failure, an opening of the mitochondrial permeability transition 
pore, and a depolarization of the inner mitochondrial membrane, which can ultimately lead to 
cell death (37). ET-1 was found to increase both cytosolic Ca2+ transient (38) and 
mitochondrial ROS production (39) and to enhance the consumption of ATP (40). It has been 
demonstrated that inhibition of ETA-Rs markedly decreased mitochondrial Ca2+ deposition 
(41) and attenuated abnormalities in Ca2+ sequestration (42).  
Interestingly, IRL-1620 alone did not significantly affect the key indices of mitochondrial 
respiratory function. The question arises whether the marked improvement in ADP-
stimulated respiration after combined treatment is due to the modulation ETA-Rs solely or 
both the ETA-Rs and ETB1-Rs. Despite the fact that IRL-1620 itself was not effective, an 
indirect action through the improvement of O2 delivery/extraction cannot be ruled out. A 
more effective O2 extraction in the tissues provides better O2 diffusion to mitochondria, 
where it can be reduced by the ETS to support ATP synthesis (43). However, it remains 
unclear whether the recovery of mitochondrial function mediated by the modulation of ET 
receptors is (1) a consequence of an improved microcirculatory dysfunction, (2) a direct 
action on the organelle, or (3) a result of both mechanisms at the same time. The direct 
mitochondrial effect of ET-1 on elevated mitochondrial ROS production has been reported 
previously (39). Nevertheless, the presence of ET receptors has only been confirmed in the 
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nucleus to date. If the receptor were located on other organelles, e.g. the mitochondria or 
endoplasmic reticulum, this would influence various signaling processes, such as calcium 
transport, respiration, or apoptosis (44). 
Despite compartmentalization, the microcirculatory and mitochondrial functions are closely 
linked under physiological circumstances. The common denominator of both mechanisms 
may be the capillary-mitochondrial oxygen gradient, which may be a decisive factor in 
mitochondrial function in sepsis. Therefore, ET receptors could indirectly influence 
mitochondrial function through the mechanism of tissue perfusion and restoration of the 
intracellular oxygen supply. The results collectively suggest that the specific ET receptor 
agonist and antagonist therapies used in our experiment, individually and in combination, 
improved the intestinal microcirculation by direct vasodilation and indirectly improved 
mitochondrial functions by restoring tissue perfusion and DO2 to cells. 
Limitation of the study 
We attempted to follow all aspects of the MQTiPSS guidelines, but antimicrobial therapy, 
one of the standard treatment modalities in clinical practice, was omitted from the protocol 
due to the known influence of these compounds on mitochondrial respiration (45). 
Furthermore, we used male rats only; thus, gender-specific effects of the treatments cannot be 
ruled out, and a mixed population with female animals should also be used in future test 
studies. Further, the timeline of the examination window was relatively short; therefore, other 
important end-points, such as mortality, should also be investigated in longer follow-up 
studies or in sepsis models with increased severity. 
CONCLUSION  
The selective ETB-R agonist countervailed the peritonitis-induced hypotension, while the 
ETA-R antagonist maintained microcirculation and oxygen dynamics. A mixed ET receptor-
targeted treatment regime may offer a novel possibility for a simultaneous microcirculatory 
Copyright © 2019 by the Shock Society. Unauthorized reproduction of this article is prohibited.
and mitochondrial resuscitation strategy by also reducing circulating ET-1 levels and 
ameliorating inflammatory indices of sepsis. Clearly, the direct relevance to human sepsis is 
uncertain, but these findings do highlight that ETA-R– ETB1-R-centered therapies may 
influence the peripheral microcirculation, which may subsequently reverse the mitochondrial 
dysfunction and perhaps the intracellular oxygen supply–demand mismatch. 
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FIGURE LEGENDS 
Figure 1. The experimental scheme. The animals were randomly assigned into sham-
operated and septic experimental groups. Twenty-two hours after sepsis induction, the 
animals were divided into 4 subgroups: treated with saline, the ETA receptor antagonist ETR-
p1/fl peptide (100 nmol kg-1 h-1 iv), the ETB1 receptor agonist IRL-1620 (0.55 nmol kg-1 h-1 
iv), or the same doses as the combination therapy. 
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Figure 2. Changes in mean arterial pressure (A), stroke volume index (B), cardiac output (C), 
and total peripheral resistance response (D) in the sham-operated group (open circles) and in 
the different sepsis groups treated with saline vehicle (black triangle), the ETA receptor 
antagonist ETR-p1/fl (grey square), the ETB1 receptor agonist IRL-1620 (grey diamond), and 
a combination of these (black hexagon with plus sign). The plots demonstrate the median 
values and the 25th (lower whisker) and 75th (upper whisker) percentiles. x P < 0.05 vs. sham-
operated; # P < 0.05 vs. vehicle-treated sepsis; * P <0.05 vs. 0 min. 
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Figure 3. Oxygen delivery (DO2) (A), oxygen consumption (VO2) (B), and oxygen 
extraction (C) in the sham-operated group (empty box) and in the different septic groups 
treated with saline (black box), the ETA receptor antagonist ETR-p1/fl (striped box), the ETB1 
receptor agonist IRL-1620 (striped box), and a combination of these (checked box). The plots 
demonstrate the median (horizontal line in the box) and the 25th (lower whisker) and 75th 
(upper whisker) percentiles. Between groups: Kruskal–Wallis test and Dunn’s post-hoc test. x 
P < 0.05 vs. sham-operated; # P < 0.05 vs. vehicle-treated sepsis. 
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Figure 4. Plasma alanine aminotransferase (ALAT) (A), urea (B), and PaO2/FiO2 ratio (C) 
and lactate levels (D) in the sham-operated group (empty box) and in the different sepsis 
groups treated with saline vehicle (black box), the ETA receptor antagonist ETR-p1/fl (striped 
box), the ETB1 receptor agonist IRL-1620 (striped box), and a combination of these (checked 
box). The plots demonstrate the median (horizontal line in the box) and the 25th (lower 
whisker) and 75th (upper whisker) percentiles. x P < 0.05 vs. sham-operated; # P < 0.05 vs. 
vehicle-treated sepsis. 
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Figure 5. Capillary perfusion rate (A), red blood cell velocity (B), plasma interleukin-6 (IL-
6) concentration (C), and plasma endothelin-1 (ET-1) (D) in the sham-operated group (empty 
box) and in the different sepsis groups treated with saline vehicle (black box), the ETA 
receptor antagonist ETR-p1/fl (striped box), the ETB1 receptor agonist IRL-1620 (striped 
box), and a combination of these (checked box). The plots demonstrate the median 
(horizontal line in the box) and the 25th (lower whisker) and 75th (upper whisker) percentiles. 
Between groups: Kruskal–Wallis test and Dunn’s post-hoc test. x P < 0.05 vs. sham-
operated; # P < 0.05 vs. vehicle-treated sepsis. 
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Figure 6. Complex I-linked OXPHOS capacity (C1-OXPHOS) (A), complex II-linked 
OXPHOS capacity (C1I-OXPHOS) (B), complex I respiration control ratio (CI-RCR) (C), 
and complex II respiration control ratio (CII-RCR) (D) in the sham-operated group (empty 
box) and in the different sepsis groups treated with saline vehicle (black box), the ETA 
receptor antagonist ETR-p1/fl (striped box), the ETB1 receptor agonist IRL-1620 (striped 
box), and a combination of these (checked box). The plots demonstrate the median 
(horizontal line in the box) and the 25th (lower whisker) and 75th (upper whisker) percentiles. 
x P < 0.05 vs. sham-operated; # P < 0.05 vs. vehicle-treated sepsis. 
 
 
 
